MENU
ACB
AS OF
Feb 13 closing price
Price
$3.55
Change
+$0.19 (+5.65%)
Capitalization
202.89M
122 days until earnings call
Intraday BUY SELL Signals
Go to the list of all blogs
Anna G's Avatar
published in Blogs
May 17, 2021
Aurora Cannabis (ACB, $6.85) misses fiscal Q3 expectations

Aurora Cannabis (ACB, $6.85) misses fiscal Q3 expectations

Aurora Cannabis  posted its fiscal third quarter results that fell short of analysts’ expectations.  

For the third quarter ended March 31, the cannabis company reported a loss of -C$0.85 a share, wider than the -C$0.25 a share loss anticipated by analysts polled by FactSet. The company’s revenue came in at C$55.2 million, compared to C$68.7 million expected by analysts.

Aurora also said that it plans to file for a new US$300 million at-the-market stock sale program. According to the company, the program would “provide maximum flexibility to pursue select acquisitions going forward, including within the U.S.”

Related Ticker: ACB

Momentum Indicator for ACB turns negative, indicating new downward trend

ACB saw its Momentum Indicator move below the 0 level on January 29, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned negative. In of the 89 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for ACB turned negative on February 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ACB entered a downward trend on February 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ACB's RSI Indicator exited the oversold zone, of 43 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ACB advanced for three days, in of 225 cases, the price rose further within the following month. The odds of a continued upward trend are .

ACB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.511) is normal, around the industry mean (29.865). P/E Ratio (19.440) is within average values for comparable stocks, (77.080). ACB's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.973). ACB has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.029). P/S Ratio (0.727) is also within normal values, averaging (113.421).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ACB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.

Notable companies

The most notable companies in this group are ZOETIS (NYSE:ZTS), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), Avadel Pharmaceuticals plc (NASDAQ:AVDL), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM), Aurora Cannabis (NASDAQ:ACB).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.94B. The market cap for tickers in the group ranges from 2.12K to 64.7B. MKKGY holds the highest valuation in this group at 64.7B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was 2%. For the same Industry, the average monthly price growth was -2%, and the average quarterly price growth was 9%. PRFX experienced the highest price growth at 400%, while SHPH experienced the biggest fall at -32%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 0%. For the same stocks of the Industry, the average monthly volume growth was -9% and the average quarterly volume growth was -22%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 53
P/E Growth Rating: 64
Price Growth Rating: 59
SMR Rating: 79
Profit Risk Rating: 90
Seasonality Score: -20 (-100 ... +100)
View a ticker or compare two or three
ACB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. ACB showed earnings on February 04, 2026. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

a licensed producer of medical marijuana in Canada

Industry PharmaceuticalsGeneric

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
3498 63 Avenue
Phone
+1 855 279-4652
Employees
1130
Web
https://www.auroramj.com
Interact to see
Advertisement
As of August 09, 2025, the financial landscape continues to showcase the dynamic rivalry between Apple Inc. (AAPL) and Tesla, Inc. (TSLA), two titans representing distinct sectors of the technology and automotive industries.
#artificial_intelligence
As of August 9, 2025, the financial landscape presents an intriguing comparison between Meta Platforms Inc. (META) and NVIDIA Corporation (NVDA), two titans in their respective industries.
#artificial_intelligence
Tickeron’s recent strides in deploy­ing AI Trading Agents built on shorter ML cycles have produced striking returns—+204% annualized on NVDA (15 min), +112% on AVGO (15 min), and +106% on KKR (5 min).
#artificial_intelligence#trading
In the rapidly evolving landscape of financial technology, artificial intelligence has emerged as a transformative force, reshaping how investors approach trading.
In the dynamic world of financial markets, artificial intelligence has emerged as a transformative force, enabling traders to navigate volatility with unprecedented precision. Tickeron, a pioneer in AI-driven trading solutions, has revolutionized this space through its innovative brokerage agents.
Tickeron, a leader in AI-driven trading solutions, today announced exceptional results from its AI Trading Agent specialized in KKR stock.
#artificial_intelligence#trading
Tickeron, a pioneer in AI-driven financial tools, today announced exceptional trading results for its AI Trading Agent focused on NVIDIA Corporation (NVDA).
#artificial_intelligence
Tickeron, a leader in AI-driven financial solutions, announces its AI Trading Agent’s remarkable 49.16% annualized return trading the iShares U.S. Aerospace & Defense ETF (ITA). Leveraging advanced Financial Learning Models (FLMs), the agent delivers exceptional results for investors targeting high-growth sectors like aviation and defense.
#artificial_intelligence
Tickeron’s AI Trend Prediction Engine (TPE) stands at the forefront of this revolution, leveraging advanced Financial Learning Models (FLMs) to deliver precise predictions for stocks, ETFs, and mutual funds
#artificial_intelligence
The financial markets in 2025 continue to demonstrate resilience amid economic uncertainties, with artificial intelligence playing a pivotal role in identifying bullish opportunities.
Tickeron, a leader in AI-driven trading solutions, today announced outstanding results from its AI Trading Double Agent, delivering a remarkable +318% annualized return on trades involving Advanced Micro Devices (AMD) and its inverse ETF (AMDS) using a 15-minute timeframe.
#artificial_intelligence
Tickeron, a leader in AI-driven financial analysis, releases a comparative analysis of Invesco QQQ Trust (QQQ) and Invesco NASDAQ 100 ETF (QQQM). Both ETFs show robust year-to-date (YTD) gains of 11.646% for QQQ and 11.703% for QQQM, highlighting their strength in tracking the NASDAQ-100 Index.
#artificial_intelligence
Tickeron releases a comparative analysis of Apple Inc. (AAPL) and Tesla Inc. (TSLA), highlighting key metrics and AI-driven insights for investors. With AAPL at $230.56 and TSLA at $329.31, both stocks are rated as a Buy based on long- and short-term analyses.
#artificial_intelligence
Tickeron, a leader in AI-driven trading solutions, releases a comparative analysis of SPDR Portfolio S&P 500 ETF (SPLG) and Vanguard S&P 500 ETF (VOO), highlighting a tight race with YTD gains of 9.865% for SPLG and 9.870% for VOO.
Tickeron, a leader in AI-driven financial solutions, announces its AI Trading Agent’s remarkable +198% annualized return on AAPU, a fund targeting 200% of Apple Inc.’s (AAPL) daily performance.
#artificial_intelligence
Tickeron, a leader in AI-driven financial solutions, proudly announces Day Trader, an algorithmic trading robot achieving a remarkable 91% annualized return. Engineered for intraday markets, Day Trader leverages pullback strategies and tactical hedging with QID and SOXS to deliver high returns while mitigating risk.
#artificial_intelligence
Tickeron’s AI-powered trading agent, focusing on TNA, UPRO, and URTY, has achieved a remarkable +62% annualized return. This long-only, 60-minute interval strategy leverages 3x ETFs to capture aggressive upside in U.S. small- and large-cap equities, showcasing the power of Tickeron’s Financial Learning Models (FLMs).
Revolutionizing Trading with AI-Powered Patterns Tickeron, a leader in AI-driven financial technology, announces its Real-Time Patterns (RTP) tool, designed to empower traders by scanning thousands of stocks, ETFs, crypto, and forex in minutes. RTP identifies high-probability trading patterns, delivering actionable insights like breakout prices, target prices, and confidence levels
#artificial_intelligence
Tickeron, a leader in AI-driven financial analytics, announces its AI Trend Prediction Engine (TPE), boasting an impressive 86% success rate in forecasting stock trends. This cutting-edge tool empowers traders with precise bullish, bearish, or sideways predictions for over 7,000 stocks, including GOOGL, GOOG, and META. Try it free for 14 days at tickeron.com.
#patterns#artificial_intelligence
In the dynamic world of financial markets, few rivalries capture investor attention like that between Coca-Cola Consolidated, Inc. (COKE) and The Coca-Cola Company (KO).